Answers are grounded in this paper and cite their sources.
A novel review uncovers ulinastatin's role in reducing organ injury in sepsis, highlighting its therapeutic promise.
Sepsis, a life-threatening systemic inflammatory response induced by infection, remains a major therapeutic challenge with high mortality rates, especially when progressing to multiple organ dysfunction syndrome (MODS). Ulinastatin (UTI), a serine protease inhibitor with anti-inflammatory and anti-oxidative properties, has emerged as a promising therapeutic candidate for sepsis-induced organ injury. This article systematically reviews recent advances in the multi-organ protective effects of UTI against sepsis, focusing on its mechanisms through modulating key signaling pathways, reducing inflammatory cytokine release, inhibiting oxidative stress, and regulating cellular apoptosis/autophagy. Clinical and preclinical evidence demonstrates UTI's efficacy in alleviating injury in critical organs including lungs, heart, liver, spleen, intestines and kidneys. The current review clarifies the mechanism by which UTI mitigates sepsis-related MODS and provide a theoretical basis for identifying potential therapeutic targets of UTI to mitigate sepsis injury.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: